Patent 8404681 was granted and assigned to Luitpold Pharmaceuticals on March, 2013 by the United States Patent and Trademark Office.
Compound that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods of inhibiting the DNA-PK biological activity, methods of sensitizing cells the agents that cause DNA lesions, and methods of potentiating cancer treatment are disclosed.